Cargando…

Remission of idiopathic retroperitoneal fibrosis by ofatumumab as a disease-modifying therapy for multiple sclerosis

Detalles Bibliográficos
Autores principales:	Hanazono, Akira, Sanpei, Yui, Shimada, Hinako, Yasuda, Keita, Takahashi, Yoshiko, Funasaka, Homare, Sagehashi, Ryuichiro, Hiroshima, Yuko, Nanjo, Hiroshi, Sugawara, Masashiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526141/ https://www.ncbi.nlm.nih.gov/pubmed/36193452 http://dx.doi.org/10.1016/j.ensci.2022.100428

Ejemplares similares

Focal brain lactate accumulation in metformin-induced encephalopathy without systemic lactic acidosis: A case report suggesting mitochondrial vulnerability in lentiform fork sign
por: Hanazono, Akira, et al.
Publicado: (2021)

Guillain-Barré Syndrome and Posterior Reversible Encephalopathy Syndrome following Spinal Surgery
por: Sanpei, Yui, et al.
Publicado: (2019)

Distressing Belching with Chorea Induced by Caudate Infarction
por: Sanpei, Yui, et al.
Publicado: (2021)

Impfungen unter Ofatumumab gelingen
por: Facharztmagazine, Redaktion
Publicado: (2023)

Ofatumumab treatment in lupus nephritis patients
por: Haarhaus, Malena Loberg, et al.
Publicado: (2016)

Role of ofatumumab in treatment of chronic lymphocytic leukemia
por: Veliz, Marays, et al.
Publicado: (2011)

Refractory pemphigus vulgaris successfully treated with ofatumumab
por: Klufas, Daniel M., et al.
Publicado: (2020)

Idiopathic Retroperitoneal Hematoma
por: Monib, Sherif, et al.
Publicado: (2011)

Idiopathic Retroperitoneal Hematoma
por: Abe, Tomoyuki, et al.
Publicado: (2010)

The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
por: Nabhan, Chadi, et al.
Publicado: (2011)

Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

Nutzen der frühzeitigen Behandlung mit Ofatumumab bestätigt
por: Linder, Isabelle
Publicado: (2022)

Pediatric idiopathic retroperitoneal fibrosis
por: Subramani, Ashwin V., et al.
Publicado: (2019)

Aphasia with No Apparent Paralysis in Progressive Stroke of the Anterior Choroidal Artery
por: Kanazawa, Serika, et al.
Publicado: (2022)

Ofatumumab: a novel monoclonal anti-CD20 antibody
por: Lin, Thomas S
Publicado: (2010)

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab
por: Laurenti, Luca, et al.
Publicado: (2016)

Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling
por: Payandeh, Zahra, et al.
Publicado: (2018)

Ofatumumab‐associated acute pneumonitis: Not new but still the first case
por: Bonanni, Alice, et al.
Publicado: (2016)

Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Tuscano, Joseph, et al.
Publicado: (2020)

Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

Nutzen der frühzeitigen MS-Behandlung mit Ofatumumab bestätigt
por: Linder, Isabelle
Publicado: (2022)

Idiopathic retroperitoneal cyst in an adult male
por: Jha, Ashesh Kumar, et al.
Publicado: (2017)

Use of rituximab in idiopathic retroperitoneal fibrosis
por: Boyeva, Veronika, et al.
Publicado: (2020)

Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol
por: Ravani, Pietro, et al.
Publicado: (2017)

The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies
por: Castillo, Jorge, et al.
Publicado: (2010)

Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia
por: Frustaci, Anna Maria, et al.
Publicado: (2015)

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
por: Bar-Or, Amit, et al.
Publicado: (2018)

Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
por: AlDallal, Salma M
Publicado: (2017)

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
por: Florou, Despoina, et al.
Publicado: (2020)

Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis
por: Kramer, John, et al.
Publicado: (2023)

Ofatumumab Desensitization Protocol: A Case of Refractory Immune Thrombocytopenic Purpura
por: Cochran, Audra L, et al.
Publicado: (2023)

A meaningful exploration of ofatumumab in refractory NMOSD: a case report
por: Zhan, Yibo, et al.
Publicado: (2023)

BRCA2 Frameshift Mutation in de novo Small-Cell Neuroendocrine Carcinoma of the Prostate: A Case Report
por: Okubo, Keisuke, et al.
Publicado: (2023)

Pathologically Proven Spontaneous Remission of IgG4-related Retroperitoneal Fibrosis
por: Yamakawa, Hideaki, et al.
Publicado: (2017)

Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins
por: Dwojak, M, et al.
Publicado: (2015)

UK experience of ofatumumab in recurrence of focal segmental glomerulosclerosis post-kidney transplant
por: Reynolds, Ben C., et al.
Publicado: (2021)

COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
por: Cross, Anne H., et al.
Publicado: (2022)

Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis
por: Yu, Huixin, et al.
Publicado: (2022)

Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis
por: von Essen, Marina Rode, et al.
Publicado: (2022)

Premature Ventricular Contractions and Cardiomyopathy while on Ofatumumab for Treatment of Chronic Lymphocytic Leukaemia
por: Odeyinka, Oladipo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ondkvs0emocqj4pqluhaai7dh4